natgillin/translations-raw huggingface dataset:
desuden begrundelsen fra LFB Biomedicaments for dettes anmodning om fornyet overvejelse af PRAC's henstilling, og synspunkterne på to ekspertmøder afholdt den 22. februar og 3. august 2017, 
PRAC also considered grounds submitted by LFB Biomedicaments as basis for their request for re-examination of the PRAC recommendation and the views of two experts meetings held on 22 February and 3 August 2017.
• Til patientrelaterede risikofaktorer hører mutation af F8-genet, hæmofiliens sværhedsgrad, etnicitet, familiær anamnese vedrørende inhibitordannelse, og muligvis HLA-DR-konstitution (Human Leukocyt Antigen-antigen D-relateret konstitution). 
• Patient-related risk factors include type of F8 gene mutation, severity of haemophilia, ethnicity, family history of inhibitor development and possibly HLA-DR (Human Leukocyte Antigenantigen D Related) constitution.
Trods den manglende substantielle evidens til underbygning af forskelle i risici mellem forskellige rFVIII-produkter kan forskelle i risiko dog ikke udelukkes, da der er tale om en sammensat produktklasse med forskelle i sammensætning og formulering. 
However, despite the lack of robust evidence to support differential risks between rFVIII products, differential risks cannot be excluded, as this is a heterogeneous product class with differences in composition and formulations.
Denne forskel blev dog ikke-signifikant, når man udelukkede patienter i Det Forenede Kongerige (også dem, der indgik i RODIN/Pednet-undersøgelsen). 
Although this became non-significant when UK patients (also included in the RODIN/Pednet study were excluded.
Ligesom i UKHCDO-undersøgelsen fandtes der i FranceCoag-undersøgelsen ikke for noget rFVIII-produkt statistisk signifikant højere risiko end for Advate, når man udelukkede franske patienter (også dem, der indgik i RODIN/Pednet-undersøgelsen). 
Like the UKHCDO study, the FranceCoag study also found no statistically significant increased risk for any rFVIII products vs Advate when French patients (also in the RODIN/Pednet study) were excluded.
Både med pdFVIII og rFVIII kan behandlingen medføre dannelse af inhibitorer (som, ved testning med Nijmegen-metoden i Bethesda-assayet, er defineret som ≥0,6 Bethesda-enheder (BU) for en "lavtiter"inhibitor og > 5 BU for en "højtiter"-inhibitor). 
Treatment with both pdFVIII and rFVIII can lead to development of inhibitors (tested with the Nijmegen method of the Bethesda assay and defined as ≥0.6 Bethesda units (BU) for “a low titre” inhibitor and >5 BU for a “high-titre” inhibitor).
Der er derfor stor usikkerhed forbundet med at ekstrapolere resultaterne af SIPPET til hele rFVIII-klassen, især til senere godkendte rFVIII-produkter, der ikke er omfattet af SIPPET-undersøgelsen. 
Therefore, there is a high degree of uncertainty around extrapolating the SIPPET findings to the entire rFVIII class, particularly for more recently-authorised rFVIII products which were not included in the SIPPET trial.
PRAC finder imidlertid, at der er usikkerheder omkring SIPPETundersøgelsens resultater, som udelukker en konklusion om, at risikoen for inhibitordannelse hos tidligere ubehandlede patienter er højere ved behandling med rFVIII-produkter end med de pdFVIIIprodukter, der er anvendt i denne kliniske undersøgelse; dette uddybes nærmere i det følgende: 
However the PRAC is of the view that there are uncertainties with regards to the findings of the SIPPET study which preclude the conclusion that there is a higher risk of inhibitor development in PUPs treated with rFVIII products than pdFVIII products studied in this clinical trial, as detailed below:
Denne usikkerhed ophæves ikke helt af de supplerende præciseringer, der er givet af SIPPET-forfatterne. 
The additional points of clarification provided by the SIPPET authors do not fully resolve this uncertainty.
For højtiter-inhibitorer var risikoforholdet 1,69 med 95 % SI [0,96; 2,98]). 
For high-titre inhibitors, the hazard ratio was 1.69 (95% CI, 0.96 to 2.98).
I CANAL-undersøgelsen2 fandtes ingen tegn på en klasseforskel, herunder pdFVIII-produkter med betydelige mængder von Willebrand-faktor; for "klinisk relevante" inhibitorer var det justerede risikoforhold 0,7 (med 95 % SI [0,4; 1,1]), og for højtiterhæmmere (≥ 5 BU) 0,8 (med 95 % SI [0,4; 
The CANAL study2 found no evidence of a class difference, including pdFVIII products with considerable quantities of von Willebrand factor; for ‘clinically relevant' inhibitors the adjusted hazard ratio was 0.7 (95% CI 0.4-1.1), and for high titre inhibitors (≥5 BU) was 0.8 (95% CI 0.4-1.3).
PRAC fandt, at SIPPET-undersøgelsen i kraft af, at den er en prospektiv, randomiseret undersøgelse, har undgået mange af de designbetingede begrænsninger ved de observationsundersøgelser og 
The PRAC considered that as a prospective randomised trial, the SIPPET study avoided many of the design limitations of the observational and registry-based studies undertaken so far to evaluate the risk of inhibitor development in PUPs.
SIPPET-undersøgelsen var en åben, randomiseret multinational multicenterundersøgelse af forekomsten af neutraliserende alloantistoffer hos patienter med svær kongenit hæmofili A (FVIIIkoncentration i plasma <1 %) ved anvendelse af enten pdFVIII- eller rFVIII-koncentrat. 
The SIPPET study was an open-label, randomized, multi-centre, multi-national trial investigating the incidence of neutralising allo-antibodies in patients with severe congenital haemophilia A (plasma FVIII
Undersøgelserne var for størstedelen enkeltarmede og tilvejebringer ikke data til en komparativ analyse (hverken mellem pdFVIII og rFVIII som klassevurdering, eller inden for rFVIII-klassen). 
Many of these studies were small and not specifically designed to evaluate the inhibitor risk in PUPs with severe haemophilia A. The studies were mostly single arm and do not provide data to perform comparative analysis (either between pdFVIII and rFVIII as a class comparison, or within the rFVIII class).
Der var desuden evidens for højere risiko med Refacto AF (endnu et 3. generations rFVIII) end med Advate, men kun for al inhibitordannelse. 
(another 3rd generation rFVIII) vs Advate, but only for all inhibitor development.
) for 2. generations rFVIII octocog alfa (Kogenate FS/Helixate NexGen) end for 3. generations rFVIII octocog alfa (dette skyldtes udelukkende data for Advate). 
However, the study found evidence of an increased risk of inhibitors (all and high titre) for 2nd generation rFVIII octocog alfa (Kogenate FS/Helixate NexGen) compared with 3rd generation rFVIII octocog alfa (which was driven solely by data for Advate).
Denne undersøgelse er kendt som SIPPET-undersøgelsen ("Survey of Inhibitors in PlasmaProduct Exposed Toddlers") (undersøgelse af inhibitorer hos småbørn, der eksponeres for plasmaprodukter). 
This trial, known as the SIPPET study (“Survey of Inhibitors in Plasma-Product Exposed Toddlers”) was conducted to evaluate the relative risk of inhibitors in patients treated with pdFVIII compared to rFVIII.
Resultater af kliniske undersøgelser, som ikke er tilstrækkeligt substantielle (f.eks. som følge af metodologiske begrænsninger), bør ikke afspejles i produktinformationen for FVIIII-produkter. 
Results of clinical studies not sufficiently robust (e.g. suffering from methodolical
Hos tidligere behandlede patienter (PTP) er der mindre tendens til forekomst af inhibitorer. 
Inhibitors are less likely to occur in previouslytreated patients (PTPs).
• SIPPET-undersøgelsens design var ikke beregnet til at vurdere risikoen for inhibitordannelse for de enkelte produkter, og undersøgelsen omfattede kun et begrænset antal FVIII-produkter. 
• The SIPPET study was not designed to evaluate the risk of inhibitor development for individual products, and included a limited number of FVIII products.
Resultaterne af SIPPETundersøgelsen såvel som af de enkelte kliniske forsøg og observationsundersøgelser er ikke tilstrækkelige til at bekræfte gennemgående statistisk og klinisk betydningsfulde forskelle i inhibitorrisiko mellem produktklasserne rFVIII og pdFVIII. 
The findings from the SIPPET study, as well as those from the individual clinical trials and observational studies, are not sufficient to confirm any consistent statistically and clinically meaningful differences in inhibitor risk between the rFVIII and pdFVIII product classes.
1 F. Peyvandi et al. “A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A” N Engl J Med. 2016 May behandlet med rFVIII-produkter, var forekomsten af alle inhibitorer 87 % højere end hos dem, der blev behandlet med pdFVIII (som indeholdt VWF) (risikoforhold 1,87 med 95 % SI [1,17; 2,96]). 
It found that patients treated with rFVIII products had an 87% higher incidence of all inhibitors than those treated with pdFVIII (which contained VWF) (hazard ratio, 1.87; 95% CI, 1.17 to 2.96).
ATCvet-kode: QI07AJ06. 
ATC vet code: QI07AJ06.
MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/14/163/001 
MARKETING AUTHORISATION NUMBER(S) EU/2/14/163/001
Farmakoterapeutisk gruppe: Immunologiske midler til canidae - levende og inaktiverede virus- og inaktiverede bakterievacciner. 
Pharmacotherapeutic group: Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.
UDLØBSDATO EXP måneder/år} 
EXPIRY DATE EXP {month/year}
Årlige revaccinationer er påkrævet for parainfluenza og Leptospira komponenter. 
Annual re-vaccination is required for Parainfluenza and Leptospira components.
Suspension (inaktiveret): L. interrogans serovar Icterohaemorrhagiae 
Suspension (inactivated) : L. interrogans serovar Icterohaemorrhagiae
I tilfælde af rejser til risikoområder eller ved rejser uden for EU, kan dyrlægen give en ekstra rabiesvaccination efter 12ugers alderen for at sikre, at de vaccinerede hunde har et antistoftiter på ≥ 0,5 IE/ml som generelt anses for tilstrækkelig beskyttelse, og at det opfylder testkrav for rejser(antistoftiter på ≥ 0,5 IE/ml). 
In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).
To doser af Versican Plus DHPPi/L4R med 3 til 4 ugers mellemrum fra 8-9-ugers alderen. 
Two doses of Versican Plus DHPPi/L4R 3-4 weeks apart from 8-9 weeks of age.
Mindst 3 år efter basisvaccination for hundesygevirus, hundeadenovirus type 1, hundeadenovirus type 2, hundeparvovirus og rabies. 
At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies.
En enkeltdosis af Versican Plus DHPPi/L4R bør indgives hvert 3. år. 
A single dose of Versican Plus DHPPi/L4R should be given every 3 years.
Vaccinen er beregnet til aktiv immunisering af raske hvalpe og hunde mod sygdomme forårsaget af hundesygevirus, hundeparvovirus, hundeadenovirus type 1 og 2, hundeparainfluenzavirus, Leptospira interrogans serogruppe Australis serovar Bratislava, Leptospira interrogans serogruppe Canicola serovar Canicola, Leptospira kirschneri serogruppe Grippotyphosa serovar Grippotyphosa og Leptospira interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae samt rabiesvirus. 
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.
OPLYSNINGER OM KORREKT ANVENDELSE Rekonstituer lyofilisat med suspension aseptisk. 
ADVICE ON CORRECT ADMINISTRATION Aseptically reconstitute the lyophilisate with suspension.
Ved behov kan hunde under 8-uger vaccineres, da sikkerheden af Versican Plus DHPPi/L4R er påvist hos hunde i 6-ugers alderen. 
In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6 weeks old dogs.
Mindst 1 år efter basisvaccination for CpiV og Leptospira komponenter. 
At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components.
INDLÆGSSEDDEL Versican Plus DHPPi/L4R lyofilisat og suspension til injektionsvæske, suspension til hund 
PACKAGE LEAFLET: Versican Plus DHPPi/L4R lyophilisate and suspension for suspension for injection for dogs
Den første dosis kan derfor administreres med Versican Plus DHPPi/L4, I så tilfælde bør den anden dosis med Versican Plus DHPPi/L4R ikke administreres tidligere end 12 ugers alderen. 
In this case the second vaccination with Versican Plus DHPPi/L4R should not be given before 12 weeks.
VETERINÆRLÆGEMIDLETS NAVN Versican Plus DHPPi/L4R - lyofilisat - til hund 
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R lyophilisate for dogs
VETERINÆRLÆGEMIDLETS NAVN Versican Plus DHPPi/L4R - suspension - til hund 
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R suspension for dogs
VETERINÆRLÆGEMIDLETS NAVN Versican Plus DHPPi/L4R lyofilisat og suspension til injektionsvæske, suspension til hund 
NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R lyophilisate and suspension for suspension for injection for dogs
− for at forebygge kliniske symptomer og udskillelse i urinen og reducere infektion forårsaget af L. interrogans serogruppe Canicola og L. interrogans serogruppe Icterohaemorrhagiae serovar Icterohaemorrhagiae 
Australis serovar Bratislava, - to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, - to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa and - to prevent mortality, clinical signs and infection caused by rabies virus.
6.5 Den indre emballages art og indhold Vaccinen leveres i hætteglas Type I. Hætteglassene med lyofilisat er lukket med en prop af brombutylgummi og et aluminiumlåg. 
Type I glass vial containing 1 dose of lyophilisate closed with a bromobutyl rubber stopper and aluminium cap.
− for at forebygge kliniske symptomer og reducere infektion og udskillelse i urinen forårsaget af L. kirschneri serogruppe Grippotyphosa serovar Grippotyphosa og 
Australis serovar Bratislava, - to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, - to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, and - to prevent mortality, clinical signs and infection caused by rabies virus.
− 3 uger efter første vaccination for CDV, CAV, CPV 
Onset of immunity: - 2 weeks after a single vaccination from 12 weeks of age for rabies, - 3 weeks after the first vaccination for CDV, CAV, CPV, - 3 weeks after completion of the primary course for CPiV and - 4 weeks after completion of the primary course for Leptospira components.
De forventede fordele af Thymanax er at reducere og gradvist fjerne symptomer relateret til Deres depression. 
The expected benefits of Thymanax are to reduce and gradually remove the symptoms related to your depression.
Thymanax bør derfor ikke anvendes til disse patienter. 
Thymanax should therefore not be used in these patients.
Kalenderen, der er trykt på blisterkortet med tabletterne, kan hjælpe Dem til at huske, hvornår De sidst har taget en Thymanax tablet. 
The calendar printed on the blister containing the tablets should help you remembering when you last took a tablet of Thymanax.
Under Deres behandling med Thymanax: 
During your treatment with Thymanax :
De må ikke tage Thymanax, hvis Deres lever ikke fungerer ordentligt. 
You must not use Thymanax if your liver does not work properly.
Børn og unge Thymanax bør ikke anvendes til børn og unge (under 18 år). 
Thymanax should not be used in children and adolescents (under 18 years old).
Nogle patienter kan få forhøjede leverenzymer i blodet under behandling med Thymanax. 
Some patients may get increased levels of liver enzymes in their blood during treatment with Thymanax.
Der skal tages beslutning om at ophøre med amning eller at seponere/afstå fra behandling med Thymanax under hensyntagen til fordelen for barnet ved amning og fordelen ved behandling for kvinden. 
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Thymanax therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Dato for første markedsføringstilladelse: 19. februar 2009 Dato for seneste fornyelse af tilladelsen: 7. januar 2019 
9 DATE OF THE FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION Date of first authorisation : 19 February 2009
Ud fra en evaluering af disse undersøgelser vil lægen afgøre, om De bør fortsætte med at bruge Thymanax eller ej (se også punkt 3, 'Sådan skal De tage Thymanax'). 
Based on the evaluation of these tests your doctor will decide whether you should receive or continue using Thymanax (see also under “How to take Thymanax” in section 3).
[EU/1/08/498/002] 14 filmovertrukne tabletter [EU/1/08/498/003] 28 filmovertrukne tabletter [EU/1/08/498/005] 56 filmovertrukne tabletter [EU/1/08/498/006] 84 filmovertrukne tabletter [EU/1/08/498/007] 98 filmovertrukne tabletter [EU/1/08/498/008] 100 filmovertrukne tabletter 
[EU/1/08/498/002] 14 film-coated tablets [EU/1/08/498/003] 28 film-coated tablets [EU/1/08/498/005] 56 film-coated tablets [EU/1/08/498/006] 84 film-coated tablets [EU/1/08/498/007] 98 film-coated tablets [EU/1/08/498/008] 100 film-coated tablets
Lægen kan fortsætte med at give Dem Thymanax, efter De har fået det bedre, for at forebygge, at depressionen vender tilbage. 
Your doctor may continue to give you Thymanax when you are feeling better to prevent your depression from returning.
Der bør kun ordineres behandling med Thymanax efter omhyggelig afvejning af fordele og risici hos patienter med risikofaktorer for leverskade f.eks.: 
Treatment with Thymanax should only be prescribed after careful consideration of benefit and risk in patients with hepatic injury risk factors e.g.:
Som en forsigtighedsforanstaltning bør Thymanax undgås under graviditet. 
As a precautionary measure, it is preferable to avoid the use of Thymanax during pregnancy.
Thymanax anvendes til voksne. 
Thymanax is used in adults.
Hvis Thymanax-behandlingen startes, mens dosis af det tidligere lægemiddel nedtrappes, må mulige abstinenssymptomer ikke forveksles med manglende tidlig virkning af Thymanax. 
If Thymanax is initiated while tapering the dosage of the previous medicine, possible discontinuation symptoms should not be confounded with a lack of early effect of Thymanax.
De må ikke tage Thymanax sammen med visse andre lægemidler (se også under 'Tag ikke Thymanax' i punkt 2): fluvoxamin (et andet middel mod depression) og ciprofloxacin (et antibiotikum) kan ændre den forventede koncentration af agomelatin i Deres blod. 
You should not take Thymanax together with certain medicines (see also under “Do not take Thymanax” in section 2): fluvoxamine (another medicine used in the treatment of depression), ciprofloxacin (an antibiotic) can modify the expected dose of agomelatine in your blood.
Indehaveren af markedsføringstilladelsen skal sikre, at alle læger, der forventes at ordinere eller anvende Thymanax, har patienthåndbøger tilrådighed til udlevering til de patienter, der får ordineret dette lægemiddel. 
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Thymanax, are provided with patient booklets to be distributed to their patients being prescribed this medicine.
Tag ikke Thymanax - hvis De er allergisk over for agomelatin eller et af de øvrige indholdsstoffer (angivet i punkt 6). 
Do not take Thymanax - if you are allergic to agomelatine or any of the other ingredients of this medicine (listed in section
Tal med lægen om, hvordan De bedst kan stoppe med det tidligere lægemiddel mod depression, når De starter med Thymanax. 
You should discuss with your doctor on the best way of stopping your previous antidepressant medicine when starting Thymanax.
Efter seponering af Thymanaxbehandling bør undersøgelser af leverfunktionen gentages indtil serumaminotransferaser vender tilbage det normale niveau. 
Following discontinuation of Thymanax therapy liver function tests should be repeated until serum transaminases return to normal.
Hos de fleste mennesker begynder Thymanax at virke mod symptomer på depression i løbet af 2 ugers behandling. 
Thymanax starts to act on symptoms of depression in most depressed people within two weeks of starting treatment.
Thymanax bør ikke anvendes til behandling af major depression hos ældre patienter med demens, da Thymanaxs sikkerhed og virkning ikke er påvist hos disse patienter. 
Thymanax should not be used for the treatment of major depressive episodes in elderly patients with dementia since the safety and efficacy of Thymanax have not been established in these patients.
Den anbefalede dosis Thymanax er 1 tablet (25 mg) ved sengetid. 
The recommended dose of Thymanax is one tablet (25 mg) at bedtime.
Det er ikke dokumenteret, at Thymanax virker hos patienter i alderen 75 år og ældre. 
Effect of Thymanax is not documented in patients aged 75 years and older.
Hvis De har dårlige nyrer, vil Deres læge foretage en individuel vurdering af, om det er sikkert for Dem at tage Thymanax. 
If you have trouble with your kidneys, your doctor will make an individual evaluation of whether it is safe for you to take Thymanax.
Thymanax filmovertrukne tabletter kan tages uden for eller i forbindelse med et måltid. 
Thymanax film-coated tablets may be taken with or without food.
INFORMATION I BRAILLESKRIFT Thymanax 25 mg 
INFORMATION IN BRAILLE Thymanax 25 mg
De har fået Thymanax til behandling af en depression. 
You have been given Thymanax to treat your depression.
Ved og efter lancering skal indehaveren af markedsføringstilladelsen sikre, at alle læger, som forventes at ordinere eller anvende Thymanax, forsynes med opdateret informationsmateriale med følgende indhold: 
The Marketing Authorisation Holder shall ensure that at launch and after launch all physicians who are expected to prescribe or use Thymanax are provided with the updated educational material containing the following:
Thymanax bør ikke anvendes til behandling af depression hos patienter under 18 år, da Thymanaxs sikkerhed og virkning ikke er påvist hos denne aldersgruppe. 
Thymanax is not recommended in the treatment of depression in patients under 18 years of age since safety and efficacy of Thymanax have not been established in this age group.
Yderligere oplysningerom Thymanax findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicine is available on the European Medicines Agency web site http://www.ema.europa.eu/
Thymanax bør anvendes med forsigtighed til patienter med bipolar sygdom, mani eller hypomani i anamnesen, og lægemidlet skal seponeres hos patienter, der udvikler maniske symptomer (se pkt. 
Thymanax should be used with caution in patients with a history of bipolar disorder, mania or hypomania and should be discontinued if a patient develops manic symptoms (see section 4.8).
• Vejledning for læger i ordination af Thymanax, inklusive et skema for monitorering af leverfunktionen. 
The Physician's guide to prescribing, including a liver monitoring scheme.
Thymanax er indiceret til behandling af major depression (moderat til svær depression) hos voksne. 
Thymanax is indicated for the treatment of major depressive episodes in adults.
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det væsentlige natriumfrit. 
Thymanax contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.